Celularity Inc. Increase (Decrease) in Accounts Payable
Celularity Inc. (CELU) reported Increase (Decrease) in Accounts Payable of $3.13 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-04-30
- Celularity Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $1.83M, a 76.85% decline year-over-year.
- Celularity Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $187.00K, a 89.06% decline year-over-year.
- Celularity Inc. increase (decrease) in accounts payable for the quarter ending 2025-06-30 was $1.09M, a 40.26% increase year-over-year.
- Celularity Inc. increase (decrease) in accounts payable for the quarter ending 2025-03-31 was $17.00K.
- Celularity Inc. increase (decrease) in accounts payable for fiscal 2025 was $3.13M, a 66.17% decline from fiscal 2024.
- Celularity Inc. increase (decrease) in accounts payable for fiscal 2024 was $9.24M, a 8.73% increase from fiscal 2023.
- Celularity Inc. increase (decrease) in accounts payable for fiscal 2023 was $8.50M.
- Celularity Inc. increase (decrease) in accounts payable for fiscal 2022 was -$2.95M, a 198.04% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $2.02M derived: sum of 2 quarters · filed 2026-04-30 | $3.11M derived: sum of 3 quarters · filed 2026-04-30 | $3.13M 10-K · filed 2026-04-30 |
| 2025-09-30 | $187.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.27M derived: sum of 2 quarters · filed 2025-11-14 | $1.29M 10-Q · filed 2025-11-14 | $9.22M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $1.10M 10-Q · filed 2025-08-29 | $9.03M derived: sum of 3 quarters · filed 2026-04-30 | $10.74M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-03-31 | $17.00K 10-Q · filed 2025-08-29 | $7.94M derived: sum of 2 quarters · filed 2026-04-30 | $9.65M derived: sum of 3 quarters · filed 2026-04-30 | $10.43M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $7.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $9.64M derived: sum of 2 quarters · filed 2026-04-30 | $10.41M derived: sum of 3 quarters · filed 2026-04-30 | $9.24M 10-K · filed 2026-04-30 |
| 2024-09-30 | $1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.48M derived: sum of 2 quarters · filed 2025-11-14 | $1.31M 10-Q · filed 2025-11-14 | $3.06M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $775.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | -$397.00K 10-Q · filed 2025-08-29 | $1.35M derived: sum of 3 quarters · filed 2025-08-29 | $2.06M derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | -$1.17M 10-Q · filed 2025-08-29 | $571.00K derived: sum of 2 quarters · filed 2025-08-29 | $1.28M derived: sum of 3 quarters · filed 2025-08-29 | $4.59M derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $2.45M derived: sum of 2 quarters · filed 2025-05-08 | $5.77M derived: sum of 3 quarters · filed 2025-05-08 | $8.50M 10-K · filed 2025-05-08 |
| 2023-09-30 | $711.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | $4.02M derived: sum of 2 quarters · filed 2024-12-06 | $6.75M 10-Q · filed 2024-12-06 | $3.51M derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | $3.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $6.04M 10-Q · filed 2024-11-07 | $2.80M derived: sum of 3 quarters · filed 2024-11-07 | $2.08M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $2.73M 10-Q · filed 2024-10-16 | -$515.00K derived: sum of 2 quarters · filed 2024-10-16 | -$1.24M derived: sum of 3 quarters · filed 2024-10-16 | -$1.55M derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | -$3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | -$3.97M derived: sum of 2 quarters · filed 2024-07-30 | -$4.28M derived: sum of 3 quarters · filed 2024-07-30 | -$2.95M 10-K · filed 2024-07-30 |
| 2022-09-30 | -$723.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03 | -$1.04M derived: sum of 2 quarters · filed 2024-01-03 | $297.00K 10-Q · filed 2024-01-03 | $1.94M derived: sum of 4 quarters · filed 2024-01-03 |
| 2022-06-30 | -$314.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.02M 10-Q · filed 2023-08-14 | $2.66M derived: sum of 3 quarters · filed 2023-08-14 | $2.39M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.33M 10-Q · filed 2023-05-22 | $2.98M derived: sum of 2 quarters · filed 2023-05-22 | $2.71M derived: sum of 3 quarters · filed 2023-05-22 | $4.26M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.37M derived: sum of 2 quarters · filed 2023-03-31 | $2.92M derived: sum of 3 quarters · filed 2023-03-31 | $3.01M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$272.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.28M derived: sum of 2 quarters · filed 2022-11-10 | $1.36M 10-Q · filed 2022-11-10 | $1.44M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.64M 10-Q · filed 2022-08-09 | $1.71M derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | $85.00K 10-Q · filed 2022-05-16 | $162.00K derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $314.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $237.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |